

**Opto Circuits FY12 Consolidated Net Sales at Rs. 2357cr., Net Profit at Rs. 572 cr.
Board Recommends Dividend of Rs. 3 per Share**

Bengaluru, India | May 22, 2012

Opto Circuits (India) Ltd. (OCI), a leading developer and manufacturer of medical equipment and interventional devices for the global markets, today announced its financial results for the fourth quarter and full year ended March 31st 2012.

The Board of Directors has recommended a dividend of Rs. 3 per share; this would be subject to approval of the shareholders at the Annual General Meeting.

Consolidated Numbers:

	Year ended			Quarter ended		
	FY12	FY11	Growth (%)	Q4FY12	Q4FY11	Growth (%)
Net Sales (Rs. cr.)	2356.85	1585.56	49	662.70	544.55	22
EBITDA (Rs. cr.)	630.06	476.49	32	165.06	139.09	19
PAT (Rs. cr.)	571.88	367.25	56	209.35	111.06	89
EPS (Rs.)	23.6	19.7	20	8.64	4.58	89

- For quarter ended 31st March 2012, Medical Equipment contributed 77% to turnover, Interventional Devices contributed 22% and other businesses contributed 1%.

Management Comments:

Mr. Vinod Ramnani, Chairman and Managing Director, OCI comments: “We have had a fantastic financial year with growth in both invasive and non-invasive segments. With new product launches and market entries, strengthened presence in emerging markets and cost-saving initiatives through integration of various businesses, we have seen a surge in our revenues. Our aim is to continue improving revenues, profitability and enhance shareholders value.”

“After having established a predominant presence in overseas markets like North America and Europe, our focus now will be in key emerging markets. Our tailored product mix to access these fast growing markets will enable us to leverage the huge demands of medical equipment in primary health and diagnostic setups here”, he added.

He also said, “We are proud to be making life saving products, one of which is the AED, and are happy to share that one of the many lives that were saved last year was of a 12 year old school girl in the United States, which was recorded on the school’s CCT camera and reported on the local news. We hope that our products continue to save precious lives in the years to come.”

Highlights for Q4FY12:

Corporate:

As part of the Heart-safe campaign, Opto Circuits presented its Powerheart® G3 AEDs to the Delhi Metro, Cochin International Airport and India Habitat Centre.

In last week of March 2012, the Board issued a bonus of 3 equity shares for every 10 equity shares held.

Medical Equipment & Consumables:

Criticare Systems, Inc.:

- Criticare Systems, Inc. signed a contract to supply vital signs monitors to major hospitals in Tyumen Oblast, Russia's third-largest province.

Cardiac Science Corporation:

- Received USFDA clearance for the sale of MySense Heart®, a revolutionary wearable Holter cardiac monitor
- Partnered with Germany-based Innovint Aircraft Interior GmbH which is a leader in the global aircraft interior and equipment market and an approved Buyer Furnished Equipment (BFE) supplier for Airbus to distribute AEDs on aircraft worldwide.

Interventional Devices & Tools:

Eurocor GmbH:

- Eurocor presented the eight month follow-up data from the Valentines Trial II Global Registry on February 7 during the iMPACT Trial Session at CRT2012 in Washington D.C., USA; with an objective to assess the efficacy of the Paclitaxel-eluting balloon DIOR® for de novo lesions at 6-9 months follow-up.
- Eurocor announced that the first patients in the Freeride study were successfully treated with the drug-eluting balloon (DEB) FREEWAY™. The randomized, prospective, multicentre clinical study involves 280 patients and aims to investigate the rate of clinically driven target lesion revascularization (TLR) using the Paclitaxel-eluting FREEWAY™ balloon in comparison to an uncoated balloon (POBA) in de-novo or restenotic lesions in the Superficial Femoral Artery (SFA) or Popliteal arteries (PI-segment).

ABOUT: Opto Circuits (India) Limited

Headquarters: Bengaluru, Karnataka, India

BSE: 532391 | NSE: OPTOCIRCU

Website: www.optocircuits.com

Opto Circuits (India) Ltd. (OCI) is an MNC in the business of design, development, manufacture and marketing of healthcare equipment and medical interventional products. The product profile includes USFDA-listed, CE-marked cardiac and vital signs monitoring systems, anesthesia and respiratory care equipment, automated external defibrillators, stents, catheters, body implants and consumables. Some of OCI's well-known brands are Cardiac Science, Criticare, Devon, Eurocor, Ormed, Mediaid and Unetixs. The company's key markets are North America, Europe and BRIC countries.

CONTACT US:

Opto Circuits (India) Ltd.

E: Media - media@optoindia.com;

Investors - ir@optoindia.com

T: +91 80 2852 1040/41/42

Adfactors PR

Neha Goenka

E: neha.goenka@adfactorspr.com

T: +91 22 2281 3565